Wafaa Abdelaziz Emam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wafaa Abdelaziz Emam has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Amena Rezk Mohammed
Medical Biochemistry Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11884, Egypt
4 shared publications Ahmed El-Shaer
Physiology Department, Faculty of Medicine, Tanta University, Tanta, 31527, Egypt
1 shared publicationAlshimaa Aboalsoud
Pharmacology Department, Faculty of Medicine, Tanta University, Tanata, Egypt
1 shared publication- Asmaa A. Abo Elqasem
Immunology, Zoology and Entomology Department, Faculty of Science, Al-Azhar University (for Girls), Nasr City, Cairo, Egypt.
1 shared publication - Asmaa A. Elmadbouly
Clinical Pathology Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo 11884, Egypt
1 shared publication - Asmaa A. Muhammed
Department of Physiology, RAK College of Medical Sciences, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah P.O. Box 11172, United Arab Emirates
1 shared publication
Latest Publications
- Open Access
- 3 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6956
Can Carica papaya Serve as an Adjunct to Semaglutide in Mitigating Diabetes-Induced Testicular Injury Through Modulation of Oxidative Stress, Inflammation, Apoptosis, and the miR-34c/miR-155–SIRT1/FOXO1 Axis? An Experimental and Chem-Bio-Informatics Study
Diabetes mellitus (DM) induces significant endocrine disruption and oxidative stress (OS) within the testes, resulting in impaired spermatogenesis, increased sperm abnormalities, and compromised reproductive function. This study aimed to evaluate the combined protective effects of Semaglutide (SEM) combined with Carica papaya (papaya) juice against type 2 diabetes-induced testicular damage in rats. Forty adult male albino rats were divided into four experimental groups: a control group, a Streptozotocin (STZ)-induced diabetic group, a diabetic group treated with SEM (0.3 mg/kg), and a diabetic group treated with SEM (0.3 mg/kg) in combination with 10% papaya juice, administered for eight weeks. Statistically significant superiority over SEM alone was observed for selected endpoints; the findings primarily support the potential of papaya as a dose-sparing adjunct rather than demonstrating uniformly enhanced efficacy. They significantly improved systemic metabolic parameters, as evidenced by reduced fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) levels and restoration of the lipid profile. Importantly, it also attenuated diabetes-induced testicular injury, as demonstrated by improved reproductive hormone levels, enhanced sperm parameters, restoration of antioxidant defenses, modulation of inflammatory and apoptotic signaling, and marked histopathological recovery of seminiferous tubular architecture. Antioxidant markers revealed a notable reduction in malondialdehyde (MDA) and cytochrome P450 2E1 (CYP2E1), along with significant increases in reduced glutathione, catalase (CAT), and superoxide dismutase (SOD). Furthermore, a marked modulation of key pro-inflammatory and pro-apoptotic mediators was observed, including forkhead box protein O1 (FOXO1), microRNA-155 (miR-155), tumor necrosis factor-alpha (TNF-α), nuclear factor kappa B cell subunit 1 (NF-κB1), interleukin-6 (IL-6), caspase-3 (CASP3), and BCL2-Associated X Apoptosis Regulator (Bax), while a significant upregulation of sirtuin-1 (SIRT1), microRNA-34c (miR-34c), and B-cell lymphoma-2 (Bcl-2) was also detected. Histopathological assessments confirmed the restoration of normal testicular architecture in the treated groups. These findings indicate that the combination strategy may have the potential to achieve dose savings while maintaining efficacy comparable to the standard-dose SEM, through the enhancement of the antioxidant defenses, modulation of inflammation, and apoptosis, specifically via the modulation of the miR-34c/miR-155 and SIRT1/FOXO1 signaling.
- 3 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6956
Open AccessCan Carica papaya Serve as an Adjunct to Semaglutide in Mitigating Diabetes-Induced Testicular Injury Through Modulation of Oxidative Stress, Inflammation, Apoptosis, and the miR-34c/miR-155–SIRT1/FOXO1 Axis? An Experimental and Chem-Bio-Informatics Study
Diabetes mellitus (DM) induces significant endocrine disruption and oxidative stress (OS) within the testes, resulting in impaired spermatogenesis, increased sperm abnormalities, and compromised reproductive function. This study aimed to evaluate the combined protective effects of Semaglutide (SEM) combined with Carica papaya (papaya) juice against type 2 diabetes-induced testicular damage in rats. Forty adult male albino rats were divided into four experimental groups: a control group, a Streptozotocin (STZ)-induced diabetic group, a diabetic group treated with SEM (0.3 mg/kg), and a diabetic group treated with SEM (0.3 mg/kg) in combination with 10% papaya juice, administered for eight weeks. Statistically significant superiority over SEM alone was observed for selected endpoints; the findings primarily support the potential of papaya as a dose-sparing adjunct rather than demonstrating uniformly enhanced efficacy. They significantly improved systemic metabolic parameters, as evidenced by reduced fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) levels and restoration of the lipid profile. Importantly, it also attenuated diabetes-induced testicular injury, as demonstrated by improved reproductive hormone levels, enhanced sperm parameters, restoration of antioxidant defenses, modulation of inflammatory and apoptotic signaling, and marked histopathological recovery of seminiferous tubular architecture. Antioxidant markers revealed a notable reduction in malondialdehyde (MDA) and cytochrome P450 2E1 (CYP2E1), along with significant increases in reduced glutathione, catalase (CAT), and superoxide dismutase (SOD). Furthermore, a marked modulation of key pro-inflammatory and pro-apoptotic mediators was observed, including forkhead box protein O1 (FOXO1), microRNA-155 (miR-155), tumor necrosis factor-alpha (TNF-α), nuclear factor kappa B cell subunit 1 (NF-κB1), interleukin-6 (IL-6), caspase-3 (CASP3), and BCL2-Associated X Apoptosis Regulator (Bax), while a significant upregulation of sirtuin-1 (SIRT1), microRNA-34c (miR-34c), and B-cell lymphoma-2 (Bcl-2) was also detected. Histopathological assessments confirmed the restoration of normal testicular architecture in the treated groups. These findings indicate that the combination strategy may have the potential to achieve dose savings while maintaining efficacy comparable to the standard-dose SEM, through the enhancement of the antioxidant defenses, modulation of inflammation, and apoptosis, specifically via the modulation of the miR-34c/miR-155 and SIRT1/FOXO1 signaling.
- 8 July 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Naringenin attenuates amiodarone-induced pulmonary fibrosis in rats via modulation of the SIRT1/NF-κB signalling pathway
Amiodarone (AMD)-induced pulmonary fibrosis (PF) is a serious adverse effect driven by oxidative stress and inflammation. Naringenin [NAR], a citrus flavonoid, possesses potent antioxidant and anti-inflammatory properties. This study investigated the protective effects of NAR against AMD-induced PF in rats, focusing on the sirtuin 1; nuclear factor Kappa -B (SIRT1/NF-κB) pathway. Thirty-two male Wistar rats were divided into four experimental groups (n = 8): control (CON), (NAR), (AMD), and AMD + NAR. In the AMD groups, PF was induced using AMD. NAR treatment was administered daily via oral gavage for five weeks. After 5 weeks, the AMD group exhibited significant alveolar damage and collagen deposition. Biochemically, AMD induced severe oxidative stress, characterized by increased malondialdehyde and nitric oxide (NO) levels. It also depleted antioxidant defences, including reduced glutathione (GSH) and superoxide dismutase (SOD). A robust inflammatory response was observed, with elevated levels of tumor necrosis factor -alpha (TNF-α), (NF-κB), and interleukin-6 (IL-6). The profibrotic cascade was activated through increased transforming growth factor beta 1(TGF-β1) and matrix metalloproteinase (MMP-2), alongside the upregulation of connective tissue growth factor (CTGF) and platelet derived growth factor (PDGF) mRNA. Apoptotic signalling was heightened by decreased B-cell lymphoma2 (Bcl-2) levels. Crucially, AMD downregulated SIRT1 and mitogen activated protein kinase (MAPK1/ERK2) mRNA expression. Conversely, NAR co-treatment significantly attenuated histopathological changes and reduced fibrosis scores. NAR effectively mitigated oxidative stress and restored antioxidant defenses. It also suppressed inflammatory and modulates anti-apoptotic signalling pathways. Notably, NAR decreased TGF-β1, MMP-2, CTGF, and PDGF, while restoring SIRT1 and MAPK1/ERK2 expression. NAR provides significant protection against AMD-induced PF by reducing oxidative stress, inflammation, and modulating anti-apoptotic signalling pathways. These effects are likely mediated through the modulation of the SIRT1/NF-κB signalling pathway. This suggests NAR as a potential therapeutic candidate for drug-induced lung injury.
- 8 July 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Naringenin attenuates amiodarone-induced pulmonary fibrosis in rats via modulation of the SIRT1/NF-κB signalling pathway
Amiodarone (AMD)-induced pulmonary fibrosis (PF) is a serious adverse effect driven by oxidative stress and inflammation. Naringenin [NAR], a citrus flavonoid, possesses potent antioxidant and anti-inflammatory properties. This study investigated the protective effects of NAR against AMD-induced PF in rats, focusing on the sirtuin 1; nuclear factor Kappa -B (SIRT1/NF-κB) pathway. Thirty-two male Wistar rats were divided into four experimental groups (n = 8): control (CON), (NAR), (AMD), and AMD + NAR. In the AMD groups, PF was induced using AMD. NAR treatment was administered daily via oral gavage for five weeks. After 5 weeks, the AMD group exhibited significant alveolar damage and collagen deposition. Biochemically, AMD induced severe oxidative stress, characterized by increased malondialdehyde and nitric oxide (NO) levels. It also depleted antioxidant defences, including reduced glutathione (GSH) and superoxide dismutase (SOD). A robust inflammatory response was observed, with elevated levels of tumor necrosis factor -alpha (TNF-α), (NF-κB), and interleukin-6 (IL-6). The profibrotic cascade was activated through increased transforming growth factor beta 1(TGF-β1) and matrix metalloproteinase (MMP-2), alongside the upregulation of connective tissue growth factor (CTGF) and platelet derived growth factor (PDGF) mRNA. Apoptotic signalling was heightened by decreased B-cell lymphoma2 (Bcl-2) levels. Crucially, AMD downregulated SIRT1 and mitogen activated protein kinase (MAPK1/ERK2) mRNA expression. Conversely, NAR co-treatment significantly attenuated histopathological changes and reduced fibrosis scores. NAR effectively mitigated oxidative stress and restored antioxidant defenses. It also suppressed inflammatory and modulates anti-apoptotic signalling pathways. Notably, NAR decreased TGF-β1, MMP-2, CTGF, and PDGF, while restoring SIRT1 and MAPK1/ERK2 expression. NAR provides significant protection against AMD-induced PF by reducing oxidative stress, inflammation, and modulating anti-apoptotic signalling pathways. These effects are likely mediated through the modulation of the SIRT1/NF-κB signalling pathway. This suggests NAR as a potential therapeutic candidate for drug-induced lung injury.
- 30 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Study of CD36 receptor gene expression in obese and non-obese chronic kidney disease patients
Chronic kidney disease (CKD) is a global health challenge accelerated by obesity. This study evaluated the association of peripheral Cluster of Differentiation 36 (CD36) mRNA expression and serum soluble CD36 (sCD36) with CKD, investigating how obesity modulates these markers. Seventy-five participants were stratified into controls (n = 25), non-obese CKD (n = 25), and obese CKD patients (n = 25). Markers were quantified via RT-qPCR and ELISA. Both CD36 mRNA and serum sCD36 significantly increased in CKD, peaking in the obese CKD group (p < 0.001). While strongly correlated across the whole cohort (r = 0.69, P < 0.001), stratified analysis revealed divergent behaviors. CD36 mRNA lost lipid associations but selectively correlated with serum urea exclusively in the obese CKD subgroup (r = 0.42, P = 0.04). Conversely, serum sCD36 maintained robust, obesity-independent correlations with pro-atherogenic lipids (triglycerides, total cholesterol, Low-Density Lipoprotein (LDL); P < 0.001) and an inverse correlation with High-Density Lipoprotein (HDL) in both CKD cohorts, losing renal associations. ROC analysis demonstrated superior diagnostic performance for serum sCD36 (Area Under the Curve (AUC) = 0.94, sensitivity 98%, specificity 84% at 0.64 ng/mL) over mRNA expression (AUC = 0.87, sensitivity 82%, specificity 88%) in discriminating CKD from controls. CD36 transcriptional and translational tiers exhibit distinct dynamics in CKD. Peripheral mRNA reflects localized uremic stress under obese conditions, whereas circulating sCD36 serves as a stable, obesity-independent indicator of systemic lipotoxicity and a potential diagnostic or associative biomarker.
- 30 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Study of CD36 receptor gene expression in obese and non-obese chronic kidney disease patients
Chronic kidney disease (CKD) is a global health challenge accelerated by obesity. This study evaluated the association of peripheral Cluster of Differentiation 36 (CD36) mRNA expression and serum soluble CD36 (sCD36) with CKD, investigating how obesity modulates these markers. Seventy-five participants were stratified into controls (n = 25), non-obese CKD (n = 25), and obese CKD patients (n = 25). Markers were quantified via RT-qPCR and ELISA. Both CD36 mRNA and serum sCD36 significantly increased in CKD, peaking in the obese CKD group (p < 0.001). While strongly correlated across the whole cohort (r = 0.69, P < 0.001), stratified analysis revealed divergent behaviors. CD36 mRNA lost lipid associations but selectively correlated with serum urea exclusively in the obese CKD subgroup (r = 0.42, P = 0.04). Conversely, serum sCD36 maintained robust, obesity-independent correlations with pro-atherogenic lipids (triglycerides, total cholesterol, Low-Density Lipoprotein (LDL); P < 0.001) and an inverse correlation with High-Density Lipoprotein (HDL) in both CKD cohorts, losing renal associations. ROC analysis demonstrated superior diagnostic performance for serum sCD36 (Area Under the Curve (AUC) = 0.94, sensitivity 98%, specificity 84% at 0.64 ng/mL) over mRNA expression (AUC = 0.87, sensitivity 82%, specificity 88%) in discriminating CKD from controls. CD36 transcriptional and translational tiers exhibit distinct dynamics in CKD. Peripheral mRNA reflects localized uremic stress under obese conditions, whereas circulating sCD36 serves as a stable, obesity-independent indicator of systemic lipotoxicity and a potential diagnostic or associative biomarker.
- Open Access
- 13 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (24) , 17446
Dysregulated miRNA-375, IL-17, TGF-β, and Microminerals Are Associated with Calpain-10 SNP 19 in Diabetic Patients: Correlation with Diabetic Nephropathy Stages
Zinc (Zn) and copper (Cu) have been shown to have the potential to improve glucose metabolism through interactions with cytokines and signaling events with multiple genes. miRNA-375 and the Calpin-10 gene are potential genetic biomarkers for the early prediction of diabetic nephropathy (DN). 128 healthy controls and 129 type 2 diabetic (T2DM) participants were matched for age and sex. Three subgroups were identified from the T2DM group: 39 patients had microalbuminuria, 41 had macroalbuminuria, and 49 patients had renal problems. Circulating miR-375 expression levels were measured via qPCR. Calpain-10 SNP 19 (rs3842570) genotyping was assessed with allele-specific PCR in all the included participants. Spectrophotometry was used to measure the concentrations of serum copper, zinc, and magnesium, while ELISA was used to measure the levels of TGF-β and IL-17. There was significant up-regulation in the expression of miR-375 and serum levels of TGF-β, IL-17, Cu, and the Cu/Zn ratio, whereas, in contrast to the control group, the Zn and Mg levels were lower in the T2DM group. The DN groups had significantly lower miR-375, TGF-β, IL-17, Mg, and Zn levels compared with the T2DM without nephropathy group. Furthermore, between TGF-β, IL-17, and miRNA-375, there were notable correlations. Calpain-10 SNP 19 genotype 22 and allele 2 were linked to a higher incidence of T2DM and DN. Significant TGF-β, Cu, Cu/Zn ratio, HbAc1, and creatinine levels, but insignificant miRNA-375 levels, were associated with genotype 22 of Calpain-10 SNP 19. interactions between the Calpain-10 SNP 19 genotype 22 and IL-17, TGF-β, mineral levels, and miRNA-375 might contribute to the aetiology of DN and T2DM and may have clinical implications for diagnosis and management.
- 13 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (24) , 17446
Open AccessDysregulated miRNA-375, IL-17, TGF-β, and Microminerals Are Associated with Calpain-10 SNP 19 in Diabetic Patients: Correlation with Diabetic Nephropathy Stages
Zinc (Zn) and copper (Cu) have been shown to have the potential to improve glucose metabolism through interactions with cytokines and signaling events with multiple genes. miRNA-375 and the Calpin-10 gene are potential genetic biomarkers for the early prediction of diabetic nephropathy (DN). 128 healthy controls and 129 type 2 diabetic (T2DM) participants were matched for age and sex. Three subgroups were identified from the T2DM group: 39 patients had microalbuminuria, 41 had macroalbuminuria, and 49 patients had renal problems. Circulating miR-375 expression levels were measured via qPCR. Calpain-10 SNP 19 (rs3842570) genotyping was assessed with allele-specific PCR in all the included participants. Spectrophotometry was used to measure the concentrations of serum copper, zinc, and magnesium, while ELISA was used to measure the levels of TGF-β and IL-17. There was significant up-regulation in the expression of miR-375 and serum levels of TGF-β, IL-17, Cu, and the Cu/Zn ratio, whereas, in contrast to the control group, the Zn and Mg levels were lower in the T2DM group. The DN groups had significantly lower miR-375, TGF-β, IL-17, Mg, and Zn levels compared with the T2DM without nephropathy group. Furthermore, between TGF-β, IL-17, and miRNA-375, there were notable correlations. Calpain-10 SNP 19 genotype 22 and allele 2 were linked to a higher incidence of T2DM and DN. Significant TGF-β, Cu, Cu/Zn ratio, HbAc1, and creatinine levels, but insignificant miRNA-375 levels, were associated with genotype 22 of Calpain-10 SNP 19. interactions between the Calpain-10 SNP 19 genotype 22 and IL-17, TGF-β, mineral levels, and miRNA-375 might contribute to the aetiology of DN and T2DM and may have clinical implications for diagnosis and management.
- 1 October 2023
- Published by Egyptian Association of Immunologists in The Egyptian journal of Immunology
- Vol. 30 (04) , 11-20
Prognostic utility of MicroRNA-221 and interleukin-6 in cerebral ischemic stroke
Cerebral ischemic stroke has a significant mortality rate and persistent impairment. The initial diagnosis of stroke occurs by magnetic resonance imaging and computed tomography. There is a strong need for more accessible, less expensive, and non-invasive methods besides the neuroimaging methods. MicroRNAs (miRNAs) are critical regulators for ischemic stroke as they are involved in stroke pathophysiology. The goal of the current study was to determine whether microRNA-221 (miR-221) could be used as a diagnostic biomarker for patients with ischemic stroke, and whether it can serve as a promising indicator of the disease severity especially if combined with interleukin-6 (IL-6). The study included 90 subjects, 45 cerebral ischemic stroke patients and 45 controls. MiR-221 was evaluated by quantitative real-time polymerase chain reaction (q-PCR) and IL-6 by enzyme-linked immunosorbent assay (ELISA). Our study results revealed that the serum miR-221 level was significantly reduced in cerebral ischemic stroke patients when compared to the control group (p<0.0001). In addition, serum miR-221 showed a significant negative correlation with cerebral stroke severity (p<0.0001), whereas serum IL-6 showed a significant positive correlation with cerebral stroke severity (p < 0.0001). We also analyzed the receiver operator characteristic (ROC) curve and found that area under the ROC curve (AUC) for severity of ischemic stroke by miR-221 was 0.97 (95% confidence intervall0.93–1, p<0.001). Notably, the combination of serum miR-221 with IL-6 for prediction of ischemic stroke severity showed both increased sensitivity/specificity (AUC=0.99, 95% confidence interval 0.96-1, p<0.001) than miR-221 alone. We concluded that miR-221 constituted a non-invasive, sensitive, and specific biomarker that could be used for diagnosis of ischemic stroke and for prediction of its severity.
- 1 October 2023
- Published by Egyptian Association of Immunologists in The Egyptian journal of Immunology
- Vol. 30 (04) , 11-20
Prognostic utility of MicroRNA-221 and interleukin-6 in cerebral ischemic stroke
Cerebral ischemic stroke has a significant mortality rate and persistent impairment. The initial diagnosis of stroke occurs by magnetic resonance imaging and computed tomography. There is a strong need for more accessible, less expensive, and non-invasive methods besides the neuroimaging methods. MicroRNAs (miRNAs) are critical regulators for ischemic stroke as they are involved in stroke pathophysiology. The goal of the current study was to determine whether microRNA-221 (miR-221) could be used as a diagnostic biomarker for patients with ischemic stroke, and whether it can serve as a promising indicator of the disease severity especially if combined with interleukin-6 (IL-6). The study included 90 subjects, 45 cerebral ischemic stroke patients and 45 controls. MiR-221 was evaluated by quantitative real-time polymerase chain reaction (q-PCR) and IL-6 by enzyme-linked immunosorbent assay (ELISA). Our study results revealed that the serum miR-221 level was significantly reduced in cerebral ischemic stroke patients when compared to the control group (p<0.0001). In addition, serum miR-221 showed a significant negative correlation with cerebral stroke severity (p<0.0001), whereas serum IL-6 showed a significant positive correlation with cerebral stroke severity (p < 0.0001). We also analyzed the receiver operator characteristic (ROC) curve and found that area under the ROC curve (AUC) for severity of ischemic stroke by miR-221 was 0.97 (95% confidence intervall0.93–1, p<0.001). Notably, the combination of serum miR-221 with IL-6 for prediction of ischemic stroke severity showed both increased sensitivity/specificity (AUC=0.99, 95% confidence interval 0.96-1, p<0.001) than miR-221 alone. We concluded that miR-221 constituted a non-invasive, sensitive, and specific biomarker that could be used for diagnosis of ischemic stroke and for prediction of its severity.
- Open Access
- 2 July 2023
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 14 (10) , 1192-1201
Non‐classical monocytes frequency and serum vitamin D3 levels are linked to diabetic foot ulcer associated with peripheral artery disease
Aims/Introduction: Peripheral artery disease (PAD) serves as a risk factor for diabetic foot ulcers (DFUs). PAD pathology involves atherosclerosis and impaired immunity. Non‐classical monocytes are believed to have an anti‐inflammatory role. 1,25‐Dihydroxy vitamin D (vitamin D3) is claimed to have immune‐modulating and lipid‐regulating roles. Vitamin D receptor is expressed on monocytes. We aimed to investigate if circulating non‐classical monocytes and vitamin D3 were implicated in DFUs associated with PAD.Materials and Methods: There were two groups of DFU patients: group 1 (n = 40) included patients with first‐degree DFUs not associated with PAD, and group 2 (n = 50) included patients with DFU with PAD. The monocyte phenotypes were detected using flow cytometry. Vitamin D3 was assessed by enzyme‐linked immunosorbent assay.Results: DFU patients with PAD showed a significant reduction in the frequency of non‐classical monocytes and vitamin D3 levels, when compared with DFU patients without PAD. The percentage of non‐classical monocytes positively correlated with vitamin D3 level (r = 0.4, P < 0.01) and high‐density lipoprotein (r = 0.5, P < 0.001), whereas it was negatively correlated with cholesterol (r = −0.5, P < 0.001). Vitamin D3 was negatively correlated with triglyceride/high‐density lipoprotein (r = −0.4, P < 0.01). Regression analysis showed that a high vitamin D3 serum level was a protective factor against PAD occurrence.Conclusions: Non‐classical monocytes frequency and vitamin D3 levels were significantly reduced in DFU patients with PAD. Non‐classical monocytes frequency was associated with vitamin D3 in DFUs patients, and both parameters were linked to lipid profile. Vitamin D3 upregulation was a risk‐reducing factor for PAD occurrence.
- 2 July 2023
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 14 (10) , 1192-1201
Open AccessNon‐classical monocytes frequency and serum vitamin D3 levels are linked to diabetic foot ulcer associated with peripheral artery disease
Aims/Introduction: Peripheral artery disease (PAD) serves as a risk factor for diabetic foot ulcers (DFUs). PAD pathology involves atherosclerosis and impaired immunity. Non‐classical monocytes are believed to have an anti‐inflammatory role. 1,25‐Dihydroxy vitamin D (vitamin D3) is claimed to have immune‐modulating and lipid‐regulating roles. Vitamin D receptor is expressed on monocytes. We aimed to investigate if circulating non‐classical monocytes and vitamin D3 were implicated in DFUs associated with PAD.Materials and Methods: There were two groups of DFU patients: group 1 (n = 40) included patients with first‐degree DFUs not associated with PAD, and group 2 (n = 50) included patients with DFU with PAD. The monocyte phenotypes were detected using flow cytometry. Vitamin D3 was assessed by enzyme‐linked immunosorbent assay.Results: DFU patients with PAD showed a significant reduction in the frequency of non‐classical monocytes and vitamin D3 levels, when compared with DFU patients without PAD. The percentage of non‐classical monocytes positively correlated with vitamin D3 level (r = 0.4, P < 0.01) and high‐density lipoprotein (r = 0.5, P < 0.001), whereas it was negatively correlated with cholesterol (r = −0.5, P < 0.001). Vitamin D3 was negatively correlated with triglyceride/high‐density lipoprotein (r = −0.4, P < 0.01). Regression analysis showed that a high vitamin D3 serum level was a protective factor against PAD occurrence.Conclusions: Non‐classical monocytes frequency and vitamin D3 levels were significantly reduced in DFU patients with PAD. Non‐classical monocytes frequency was associated with vitamin D3 in DFUs patients, and both parameters were linked to lipid profile. Vitamin D3 upregulation was a risk‐reducing factor for PAD occurrence.